Core Viewpoint - The company, Shantou Ultrasound Instrument Research Institute Co., Ltd., is experiencing fluctuations in stock performance and is involved in the medical imaging and industrial non-destructive testing equipment sectors, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasound Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. The company specializes in the research, development, production, and sales of medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company had a total of 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 circulating shares per person, an increase of 39.99% [8]. Market Activity - On October 30, the company's stock price fell by 3.20%, with a trading volume of 79.15 million yuan and a turnover rate of 5.57%, resulting in a total market capitalization of 10.366 billion yuan [1]. - The main capital inflow for the day was negative at 13.40 million yuan, indicating a trend of capital reduction over the past three days [4]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, a decrease of 388,200 shares from the previous period. Other notable shareholders include Yuanxin Yongfeng Medical Health A and Hong Kong Central Clearing Limited [9].

公司董事吴宏豪先生就上述情况作出书面说明如下：公司于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开第二届董事会第九次会议、第二届董事会第十次会 议，本人因公务原因，连续两次未能亲自出席董事会会议，已委托董事周宏策先 生代表本人出席上述会议，本人对上述董事会会议作出的决议均无异议。 特此公告。 证券代码：301602 证券简称：超研股份 公告编号：2025-051 汕头市超声仪器研究所股份有限公司 关于董事连续两次未亲自出席董事会会议的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）分别于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开了第二届董事会第九次会议、第二届董事会 第十次会议，公司董事吴宏豪先生因公务原因连续两次未亲自出席上述董事会会 议，委托董事周宏策先生出席并表决。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作（2025 年修订）》第 3.3.4 规定"连续两次未亲自出席董事会会议，董 事应当作出书面说明并对 ...

Core Viewpoint - The company, Chaoyan Co., Ltd., has experienced a decline in stock performance and financial metrics, indicating potential challenges in its operational performance and market position [1][2]. Financial Performance - As of September 30, 2025, Chaoyan Co., Ltd. reported a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2]. - The net profit attributable to shareholders for the same period was approximately 88.94 million yuan, reflecting a decline of 3.66% year-on-year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to approximately 43.69 million yuan [2]. Stock and Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per shareholder increased by 39.99% to 3,438 shares [2]. - The total financing balance for Chaoyan Co., Ltd. is approximately 96.65 million yuan, accounting for 6.63% of its market capitalization [1]. Institutional Holdings - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [3]. - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3]. - Other notable changes include Hong Kong Central Clearing Limited increasing its holdings by 62,000 shares to 532,000 shares [3].

Group 1 - The company, Chao Yan Co., reported a revenue of approximately 254 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 2.9% [1] - The net profit attributable to shareholders of the listed company was approximately 88.94 million yuan, a year-on-year decrease of 3.66% [1] - The basic earnings per share were 0.21 yuan, reflecting a year-on-year decrease of 16% [1]

Core Viewpoint - Chao Yan Co., Ltd. (301602.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90% [1] - The net profit attributable to shareholders was 88.94 million yuan, reflecting a year-on-year decrease of 3.66% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.19 million yuan, showing a slight decrease of 0.03% year-on-year [1] - Basic earnings per share stood at 0.21 yuan [1]

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 使用募集资金置换投入募投项目自筹资金 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法（2025 修正）》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》《上市公司募集资金监管 规则》等有关规定，对超研股份使用募集资金置换投入募投项目自筹资金事项进行了 审慎核查，发表核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元，募集资金总额 为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募 集资金净额为人 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第二届董事会第十次会议，审议通过了《关于使用募集资金置换投入 募投项目的自筹资金的议案》，同意公司使用募集资金置换投入募投项目的自筹 资金。现将有关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已 完成首次公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元， 募集资金总额为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不 含税），公司实际募集资金净额为人民币 384,363,201.32 元，募集资金已于 2025 年 1 月 17 日划至公司指定账户。华兴会计师事务所（特殊普通合伙）对公司本 次公开发行股票的资金到位情况进行了审验，并于 2025 年 1 月 17 日出具了《验 资报告》（华兴验字〔2025〕2 ...

汕头市超声仪器研究所股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 汕头市超声仪器研究所股份有限公司（以下简称"公司"）第二届董事会第 十次会议于 2025 年 10 月 28 日以现场方式在汕头市龙江路 3 号汕头市超声仪器 研究所股份有限公司 1 楼会议室召开。此前公司于 2025 年 10 月 17 日以电子邮 件、微信、电话等方式向全体董事发出会议通知。 本次会议应出席董事 9 人，实际出席董事 9 人（其中：委托出席的董事人数 1 人），董事吴宏豪先生因公务无法亲自出席会议，委托董事周宏策先生出席会 议。公司部分高级管理人员列席了本次会议。会议由董事长李德来先生主持。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中华人 民共和国证券法》等法律、法规、规范性文件和《公司章程》的相关规定。 证券代码：301602 证券简称：超研股份 公告编号：2025-048 2、审议通过《关于使用募集资金置换投入募投项目的自筹资金的议案》。 经审议，董事会认为：公司使用募集资金 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥69,929,018.69, a decrease of 31.07% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,499,021.09, down 40.69% year-on-year[4] - The basic earnings per share decreased by 44.44% to ¥0.05, while diluted earnings per share also fell by 44.44% to ¥0.05[4] - Total revenue for the current period is ¥253,606,900.34, a decrease of 2.16% from ¥261,170,540.28 in the previous period[18] - Net profit for the current period is ¥88,944,481.22, down 3.66% from ¥92,321,637.60 in the previous period[19] - The total comprehensive income for the current period is ¥89,342,559.55, a decrease from ¥92,491,503.99 in the previous period, reflecting a decline of approximately 3.7%[20] - Basic and diluted earnings per share for the current period are both ¥0.21, down from ¥0.25 in the previous period, representing a decrease of 16%[20] Assets and Liabilities - Total assets increased by 40.39% to ¥1,412,413,645.76 compared to the end of the previous year[4] - Current assets rose to ¥1,288,085,508.61, up 46.49% from ¥879,665,743.61 at the beginning of the period[16] - Total liabilities decreased to ¥110,843,896.09 from ¥135,377,063.86, a decline of 18.14%[17] - The company's equity increased significantly to ¥1,301,569,749.67 from ¥870,660,773.85, marking a growth of 49.43%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,080,448.02, down 8.03%[4] - Cash inflow from operating activities totaled ¥323,042,024.98, an increase from ¥258,619,893.23 in the previous period, marking a growth of approximately 25%[21] - Net cash flow from operating activities is ¥63,080,448.02, down from ¥68,588,538.39 in the previous period, indicating a decline of about 8%[21] - Cash inflow from investment activities is ¥1,572,662,164.31, a decrease from ¥2,357,317,461.91 in the previous period, reflecting a decline of approximately 33%[22] - Net cash flow from investment activities is -¥23,375,488.23, worsening from -¥5,673,376.00 in the previous period[22] - Cash inflow from financing activities is ¥401,633,651.91, with cash outflow for dividend distribution and interest payments totaling ¥43,689,590.81[22] - The net increase in cash and cash equivalents for the current period is ¥375,611,864.95, compared to an increase of ¥58,039,045.05 in the previous period[22] - The ending balance of cash and cash equivalents is ¥578,090,968.49, significantly higher than ¥152,580,166.72 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,970[9] - The largest shareholder, Shantou Ultrasonic Asset Management Co., Ltd., holds 51.32% of shares, totaling 219,830,247 shares[9] - The second-largest shareholder, Shantou Municipal Government State-owned Assets Supervision and Administration Commission, holds 31.14% of shares, totaling 133,369,945 shares[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 84%[9] - The company has no preferred shareholders as of the reporting period[11] - There are no changes in the number of restricted shares for the major shareholders during the reporting period[12] - The total number of restricted shares at the end of the period is 369,975,714 shares[13] - The company plans to release some restricted shares in 2026, with specific dates for each shareholder[12] - The company has not reported any related party transactions among the top shareholders[10] Operational Insights - The company received government subsidies amounting to ¥5,359,015.20 during the reporting period[5] - Accounts receivable decreased by 50.92% to ¥23,717,480.19, primarily due to the collection of receivables[7] - Inventory increased by 37.66% to ¥149,882,508.32, mainly due to increased reserves of imported raw materials[8] - Research and development expenses for the current period were ¥39,350,225.93, an increase of 8.63% compared to ¥36,954,438.09 in the previous period[18] - The company reported a financial income of ¥18,894,748.75, which is an increase from ¥8,715,395.36 in the previous period[18] - The fair value change loss was recorded at -¥258,786.86, compared to a loss of -¥1,263,030.84 in the previous period, indicating an improvement[19] - The company has a strategic plan for future growth, focusing on market expansion and new product development[14] Audit Status - The company has not undergone an audit for the third quarter financial report[23]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company's overseas revenue accounted for 55.26%, benefiting from the depreciation of the RMB [3]. Market Activity - On October 28, the company's stock rose by 0.76%, with a trading volume of 57.19 million yuan and a turnover rate of 3.90%, bringing the total market capitalization to 10.755 billion yuan [1]. - The stock has seen a net outflow of 1.2384 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Product and Innovation - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pets, horses, and livestock, and engaged with industry experts on animal healthcare development [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2].